3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
21
Phase 3
9
Phase 1
9
Phase 1/2
2
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
NIH
3
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Cyclophosphamide
250
Radiotherapy
172
pembrolizumab
155
Carboplatin
147
Gemcitabine
139
Nivolumab
135
Paclitaxel
129
Dexamethasone
119
Cisplatin
118
fludarabine
115
Rituximab
104
Lenalidomide
103
Bevacizumab
99
Docetaxel
97
Capecitabine
97
fludarabine phosphate
92
Temozolomide
89
Cytarabine
89
Oxaliplatin
87
Etoposide
82
Filgrastim
77
Irinotecan
73
Doxorubicin
73
venetoclax
70
Peripheral Blood Stem Cell Transplantation
68
Fluorouracil
68
Radiosurgery
66
Melphalan
66
Everolimus
66
Bortezomib
66
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
OTHER
×
Hydroxyurea
×
Clear all
NCT06199557
2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2
Recruiting
48 enrolled
NCT02480608
2015-06-24
CML2004
University of Leipzig
Phase 1/2
Completed
113 enrolled